Search results
12 lip 2024 · This guidance document provides recommendations to clinicians for treatment of infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and difficult-to-treat Pseudomonas aeruginosa (DTR-P. aeruginosa).
- Infection Prevention & Control
IDSA/SHEA: Primer on Healthcare Epidemiology, Infection...
- Guideline Development Process
Because of the large number of clinical practice guidelines...
- Ebola
What is Ebola? Ebola virus disease is a severe illness that...
- Evaluation and Management Services
Dr. Timothy Sullivan, Vice Chair of IDSA’s Coding & Payment...
- Bio-Preparedness Workforce Pilot
On Thursday, June 15, in Washington, D.C., Axios health care...
- Lyme Disease
IDSA engages in advocacy efforts that support better Lyme...
- ID Match
The IDSA ID Match Resolution provides guiding principles for...
- Hepatitis C
Viral hepatitis is a silent epidemic. According to the...
- Infection Prevention & Control
19 kwi 2022 · A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections reviewed, updated, and expanded previously developed questions and recommendations about the treatment of ESBL-E, CRE, and DTR-P. aeruginosa infections. Because of differences in the epidemiology of resistance and availability of specific ...
17 paź 2024 · Decolonization is an effective measure to prevent colonized patients from progressing to ESBL-E/CRE infection and can control the spread of ESBL-E/CRE in the population at source.
11 kwi 2024 · ESBL-producing Enterobacterales can cause several different infections, including urinary tract and bloodstream infections. These bacteria can also live in a patient without causing infection or symptoms, known as colonization.
27 paź 2020 · This guidance document provides recommendations for the treatment of infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).
13 sty 2022 · Prevalence of extended-spectrum beta-lactamase-producing-Enterobacteriaceae (ESBL-E) has risen in patients with urinary tract infections. The objective of this study was to determine explore the risk factors of ESBL-E infection in hospitalized patients and establish a predictive model.
Our colleagues suggest that third-generation cephalosporin MIC criteria (e.g. ceftriaxone MICs ≥2 mg/L) is a sufficient and suitable proxy for ESBL production among Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca and Proteus mirabilis. 1 We contend that this practice is misguided as it: (i) is inaccurate; (ii) encourages ...
